Related Experiment Video

Updated: Mar 29, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Medication Adherence and Health Insurance/Health Benefit in Adult Diabetics in Kingston, Jamaica

R J Bridgelal-Nagassar1, K James2, R P Nagassar3

  • 1Primary Care, North West Regional Health Authority, Trinidad and Tobago,

The West Indian Medical Journal
|December 10, 2015
PubMed

Insights

Diabetic patients in Kingston, Jamaica, with health insurance or health benefits showed significantly higher medication adherence. This highlights the importance of health coverage for managing diabetes effectively.

Area of Science:

  • Public Health
  • Epidemiology
  • Health Services Research

Background:

  • Medication adherence is crucial for managing diabetes mellitus.
  • Access to health insurance or health benefits may influence medication adherence.
  • Understanding this association is vital for improving patient outcomes in Jamaica.

Purpose of the Study:

  • To determine the association between health insurance/health benefit and medication adherence.
  • To investigate this relationship among adult diabetic patients in Kingston, Jamaica.

Main Methods:

  • Cross-sectional study conducted in two selected health centers in Kingston, Jamaica.
  • Convenience sampling of 260 adult diabetic patients (over 18 years).
  • Interviewer-administered questionnaire assessing health insurance/benefit and self-reported medication usage; Chi-squared test for analysis.

Main Results:

  • 75% of diabetic patients had health insurance/benefit; 33% overall medication non-adherence.
  • Among patients with health insurance/benefit, 71.5% were adherent versus 28.5% non-adherent.
  • A statistically significant association was found between having health insurance/benefit and medication adherence (χ2 = 6.553, p = 0.01).

Conclusions:

  • Diabetic patients in Kingston with health insurance/benefit are more likely to be medication adherent.
  • Health insurance/benefit appears to be a significant factor in medication adherence for this population.
  • Findings suggest that improving health coverage may enhance diabetes management in Jamaica.
Abstract

Keywords:
Diabeteshealth insurancemedication adherence

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.4K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
339
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.1K